About PharmaIn

About Us

PharmaIN is developing novel treatments for patients with advanced liver cirrhosis and cancer

We are a clinical-stage biopharmaceutical company dedicated to developing first- and best-in-class subcutaneous therapies through peptide engineering.

The patient experience is at the center of everything we do

We are dedicated to improving patient outcomes through innovative therapies that are both effective and easily administered, whether in outpatient or inpatient settings. Our vision is to transform the lives of patients by providing therapeutic solutions that address urgent unmet medical needs. Our cutting-edge, self-injectable medications offer a more convenient and accessible treatment option, particularly for outpatient care, enabling patients to manage their health with greater ease and confidence while also supporting continuity of care during inpatient treatment when needed.

Led by professionals with deep expertise in drug development, biotechnology and healthcare

Our leadership brings a wealth of knowledge and a strong commitment to delivering transformative therapies that not only improve clinical outcomes but also enhance the quality of life for patients.

Leadership Team

Elijah Bolotin, PhD
President, Chief Executive Officer and Board Member

Dr. Elijah Bolotin blends science and business to advance peptide-based technologies and therapeutics for liver disease, cancer, and other serious and underserved diseases. With 20+ years in biopharma, he held senior roles in Endorex joint ventures with Elan and Novo Nordisk, is an inventor on numerous issued and pending patents, and has guided PharmaIN to $75M+ in funding from the NIH, investors, and strategic partners—including Shionogi and Asahi Kasei Ventures.

Dr. Bolotin received his PhD in biochemistry and pharmaceuticals from The Hebrew University, Israel.

Elijah Bolotin, PhD
President & Chief Executive Officer

Andy Stubbs, PhD
Chief Development Officer

Dr. Andy Stubbs has over 20 years of experience in the pharmaceutical/biotechnology industry, latterly assuming global-lead roles across Medical Affairs and Clinical Development in oncology. He has extensive cell-therapy expertise across four cell therapy platforms and was formerly responsible for launching the world’s first approved cell therapy in the EU.

Before joining PharmaIN, Dr. Stubbs was global lead for NK cell therapy, clinical development at Sanofi. Earlier in his career, he spent a decade in academia, concluding as an Assistant Professor at the University of Colorado Health Sciences Center.

Dr. Stubbs received his PhD in molecular genetics from the Liverpool School of Tropical Medicine, followed by postdoctoral research at Imperial College, London.

Andy Stubbs, PhD
Chief Development Officer

Jenny Martin, RN
VP, Clinical Operations

Ms. Jenny Martin brings over 20 years of experience in establishing and leading clinical operations within biotechnology and pharmaceutical clinical development organizations. Most recently, she has led the development of Clinical Operations teams in cell therapy for hematology and oncology indications, including T-cell and NK cell therapies at Sanofi and Juno Therapeutics. Earlier in her career, Ms. Martin worked as a nurse at several hospitals and managed an active clinical trials group and academic research organization at the University of Washington.

Ms. Martin received her B.S. in nursing at Southern Oregon University.

Jenny Martin, RN
VP, Clinical Operations

Lorraine Tracey, PhD
VP, Clinical Development

Dr. Lorraine Tracey is Vice President of Clinical Development at PharmaIN Corporation, leading the advancement of peptide-based therapeutics for liver diseases and cancer. She brings over 20 years of experience in clinical development, specializing in oncology, immunotherapy, and advanced drug delivery systems.

Previously, Dr. Tracey held key roles at Sanofi as Project Lead and Associate Clinical Research Director in Early Oncology Development, where she designed and executed trials for novel cell-based immuno-oncology agents. At Kiadis Pharma, she served as Director of Clinical and Medical Affairs, advancing cell-based immunotherapies. She also contributed to oncology and endocrinology programs at Ipsen and Teva Pharmaceuticals. Her expertise spans all phases of development, from early-phase trials to regulatory submissions and post-marketing studies.

Dr. Tracey holds a Ph.D., in Molecular Medicine and M.A., and B.A. in Human Genetics from Trinity College Dublin.

Lorraine Tracey, PhD
VP, Clinical Development

Gerardo Castillo, PhD
VP, IP and Grants/Distinguished Scientist

Dr. Castillo Gerry brings over 25 years of expertise in clinical chemistry, analytical biochemistry, drug development, and drug delivery. He is a highly accomplished grant writer, securing funding for numerous projects, and a prolific author and presenter. As a registered patent agent, he has successfully prosecuted numerous patents and is credited as an inventor on more than 100.

His professional experience includes drug discovery at the University of Washington in collaboration with Novo Nordisk, as well as leadership roles as Director of Biochemistry and Drug Discovery Leader at ProteoTech Inc.

Dr. Castillo earned his Ph.D. in Clinical Biochemistry from the University of Toronto, an M.S. in Clinical Chemistry from the University of Windsor, and a B.S. in Biochemistry from the University of Saskatchewan.

Gerardo Castillo, PhD
VP, IP and Grants & Distinguished Scientist

Shawn Iadonato, PhD
Advisor

Dr. Shawn Iadonato is a biotechnology entrepreneur and executive with extensive experience founding, funding, and building public and private biotech companies. He has led teams from discovery through Phase 2 development in oncology, inflammation, and infectious diseases, and has a proven track record in private and public financing, including taking a company public in the U.S.

As CEO of Kineta Inc. (2016–2024), he raised ~$100M and secured major partnerships, including $525M with Pfizer, $360M with Genentech/Roche, and a collaboration with Merck. Earlier, as Kineta’s CSO, he advanced multiple programs, completed international regulatory submissions, and obtained $30M in non-dilutive funding.

Previously, Dr. Iadonato co-founded Illumigen Biosciences, raising ~$20M and achieving a $347M acquisition by Cubist Pharmaceuticals. He began at the University of Washington Genome Center, holds over 35 U.S. patents.

Dr. Iadonato earned his PhD in Genetics from the University of Washington and BA in Biology from the University of Pennsylvania.

Shawn Iadonato, PhD
Advisor

Board of Directors

Craig Philips
Chairman of the Board

Mr. Craig W. Philips is the Board Chair of PharmaIN Corporation and has over 30 years of pharmaceutical industry experience across Fortune 500 and biotech companies. He served as President of Kineta, a Seattle-based immuno-oncology company, holding various executive roles since 2013 until its acquisition in 2025.

Previously, Mr. Philips was President of CTI Biopharma, where he led commercial and development operations in the U.S. and EU and managed business development activities. Throughout his career, he has held strategic leadership roles in the U.S., Asia, Australia, and Europe, launching four specialty pharmaceutical products that each exceeded $1 billion in sales.

Mr. Philips serves on the boards of several biotech companies and Life Science Washington. He has been a commercial advisor to the Fred Hutchinson Cancer Research Center and the University of Washington. He also co-founded specialty pharma companies, including CounterX Therapeutics, Abacus Bioscience, and PVP Biologics.

Mr. Philips holds a BS in Business Administration and an MBA from The Ohio State University.

Craig Philips
Chairman of the Board

Elijah Bolotin, PhD
President, Chief Executive Officer and Board Member

Dr. Bolotin received his PhD in biochemistry and pharmaceuticals from The Hebrew University, Israel.

Elijah Bolotin, PhD
Board Member

Mike Shetzline, MD, PhD
Board Member

Dr. Shetzline is Senior Vice President, Chief Medical Officer, and Head of Research and Development at Ironwood Pharmaceuticals. A gastroenterologist and internist, he brings over 25 years of experience spanning biopharmaceutical leadership and academia.

He previously served as Vice President and Head of Gastroenterology Clinical Sciences at Takeda, leading global development for all GI assets. Prior roles include Vice President and Global Head of Gastroenterology at Ferring, and Vice President and Global Program Head at Novartis, overseeing programs across multiple therapeutic areas and GI discovery. Earlier, he was Gastroenterology Program Director and Assistant Professor of Medicine at Duke University Medical Center.

Dr. Shetzline earned his M.D. and Ph.D. in physiology and medicine from The Ohio State University, completed his internal medicine residency and GI fellowship at Duke, and is board certified in internal medicine. He is a Fellow of ACP, ACG, and AGA, with over 40 publications and book chapters.

Mike Shetzline, MD, PhD
Board Member